annual Report 2009 - STRATEC Biomedical AG

More documents

Recommendations

Info

Objectives for 2010 Our budgets are based on the assumption that component prices will remain within at moderate levels and rise slightly. Due in particular to economic and timing (time-to-market) considerations, our customers are focusing on their core business of reagent development. The resultant need to outsource instrumentation development and production, supplemented by our technological leadership and superb reputation, strengthens us in our assumption that we will continue to be able to grow considerably faster than the market. Our development quota remains considerably higher than that of comparable benchmark companies. In view of the projects currently in the initiation and development stages, we assume that we will grow at least twice as fast on average as the overall market in the coming years. Our efforts to increase our margins in the medium term are principally based on the following factors: The indicators available to us, such as the development status of existing development projects, as well as incoming orders figures, point to an ongoing positive business performance. The structure of our contracts, which include purchase forecasts and forecasting systems, provides us with visibility concerning our production activities and a very good budgeting horizon for analyzer system sales volumes over the terms of the individual contracts. Although there will be a further increase in the cost of system developments, particularly as a result of increasing complexity and regulatory requirements, we expect to achieve further substantial sales and earnings growth in the coming years. Birkenfeld, March 19, 2010 STRATEC Biomedical Systems AG The Board of Management • The extension of our technology pool accompanied by increasing complexity of the analyzer systems, in particular due to portfolio transactions from the technology pools of our subsidiaries Sanguin and Invitek and due to the ever higher technological standards expected of our automation solutions. Both factors are accompanied by rising barriers to entry for potential competitors. • Further fixed cost degression due to additional volume growth and the introduction of line production concepts. • Further growth in the base of STRATEC analyzer systems already installed and the resultant demand for replacement parts and consumables. Hermann Leistner Marcus Wolfinger Bernd M. Steidle 44 stratec Annual Report 2009
Report of the board of Management Report of the supervisory board THE share Corporate Governance Group Management report Consolidated financial statements Service Consolidated Financial Statements as of December 31, 2009 of STRATEC Biomedical Systems AG Consolidated Balance Sheet 46 Consolidated Statement of Comprehensive Income 48 Consolidated Cash Flow Statement 49 Statement of Changes in Group Shareholders’ Equity 50 Notes to the Consolidated Financial Statements 52 Development in Intangible Assets and Property, Plant and Equipment 110 Responsibility Statement 112 AUDIT OPINION OF GROUP AUDITOR 113 Board of Directors 114 stratec Annual Report 2009 45
Page 1 and 2: 2009 Annual Report
Page 3 and 4: Key figures at a glance and Locatio
Page 5 and 6: committed to quality proven partner
Page 7 and 8: Report of the board of Management R
Page 13 and 14: 6:50 7:30 7.00 a.m. Getting ready t
Page 15 and 16: 10:38 11:40 8.38 a.m. Talking to th
Page 17 and 18: 3:08 4:12 1.55 p.m. Analyzing the b
Page 19 and 20: 6:55 7:25 4.20 p.m. Getting the res
Page 21 and 22: 10:08 10:20 Just one example of wha
Page 47: Report of the board of Management R
Page 99 and 100:
Report of the board of Management R
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
show all

annual Report 2009 - STRATEC Biomedical AG

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?